{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:49:53Z","timestamp":1791078593527,"version":"4.1.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.pnpbp.2010.11.023","type":"journal-article","created":{"date-parts":[[2010,11,25]],"date-time":"2010-11-25T09:23:09Z","timestamp":1290676989000},"page":"380-389","source":"Crossref","is-referenced-by-count":63,"title":["Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases"],"prefix":"10.1016","volume":"35","author":[{"given":"C.","family":"Gibrat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2010.11.023_bb0005","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s007010070096","article-title":"GDNF induces recovery of the nigrostriatal dopaminergic system in the rat brain following intracerebroventricular or intraparenchymal administration","volume":"142","author":"Aoi","year":"2000","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0010","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/01616412.2000.11740761","article-title":"Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system","volume":"22","author":"Aoi","year":"2000","journal-title":"Neurol Res"},{"issue":"10","key":"10.1016\/j.pnpbp.2010.11.023_bb0790","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1073\/pnas.2628045100","article-title":"A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila","volume":"100","author":"Apostol","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0020","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/nm1102-1185","article-title":"Pharmacological prevention of Parkinson disease in Drosophila","volume":"8","author":"Auluck","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0025","first-page":"639","article-title":"Importance for radioprotective effect in mammals of pharmacological and biochemical actions of cysteamine and related substances","volume":"1","author":"Bacq","year":"1965","journal-title":"Ann Ist Super Sanit\u00e0"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1471-4159.2004.02839.x","article-title":"Tissue transglutaminase contributes to disease progression in the R6\/2 Huntington's disease mouse model via aggregate-independent mechanisms","volume":"92","author":"Bailey","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0035","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.neurobiolaging.2005.04.001","article-title":"The protective effects of cystamine in the R6\/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase","volume":"27","author":"Bailey","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0040","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1523\/JNEUROSCI.4601-04.2005","article-title":"Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta","volume":"25","author":"Baquet","year":"2005","journal-title":"J Neurosci"},{"issue":"Suppl 3","key":"10.1016\/j.pnpbp.2010.11.023_bb0045","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1002\/ana.10479","article-title":"Bioenergetic approaches for neuroprotection in Parkinson's disease","volume":"53","author":"Beal","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cell.2009.03.024","article-title":"A Nurr1 pathway for neuroprotection","volume":"137","author":"Bensinger","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0055","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1128\/MCB.24.16.7214-7224.2004","article-title":"Vanin-1\u2212\/\u2212 mice exhibit a glutathione-mediated tissue resistance to oxidative stress","volume":"24","author":"Berruyer","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0060","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0006-2952(02)01174-7","article-title":"Glutathione, iron and Parkinson's disease","volume":"64","author":"Bharath","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0065","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1101\/gad.841400","article-title":"Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system","volume":"14","author":"Bibel","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jmv.1890220108","article-title":"Effect of antiviral substances on hepatitis A virus replication in vitro","volume":"22","author":"Biziagos","year":"1987","journal-title":"J Med Virol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0075","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0304-3940(94)90684-X","article-title":"Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease","volume":"172","author":"Boka","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0085","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pages","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0090","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/j.1471-4159.2010.06874.x","article-title":"Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases","volume":"114","author":"Bousquet","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0095","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00726-009-0428-3","article-title":"Critical role of transglutaminase and other stress proteins during neurodegenerative processes","volume":"38","author":"Caccamo","year":"2010","journal-title":"Amino Acids"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.expneurol.2010.04.008","article-title":"Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription","volume":"224","author":"Calkins","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0105","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ncl.2009.04.001","article-title":"Huntington disease and other choreas","volume":"27","author":"Cardoso","year":"2009","journal-title":"Neurol Clin"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/hmg\/8.4.673","article-title":"Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3\/MJD and suppression of polyglutamine aggregation in vitro","volume":"8","author":"Chai","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0115","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.nbd.2005.12.007","article-title":"Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons","volume":"22","author":"Chang","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02815097","article-title":"The effects of oxidative stress on in vivo brain GSH turnover in young and mature mice","volume":"30","author":"Chang","year":"1997","journal-title":"Mol Chem Neuropathol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0125","first-page":"635","article-title":"Genetic polymorphisms in Parkinson's disease","volume":"19","author":"Checkoway","year":"1998","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00001648-199905000-00023","article-title":"Epidemiologic approaches to the study of Parkinson's disease etiology","volume":"10","author":"Checkoway","year":"1999","journal-title":"Epidemiology"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-0-387-33504-9_3","article-title":"Cysteamine dioxygenase: evidence for the physiological conversion of cysteamine to hypotaurine in rat and mouse tissues","volume":"583","author":"Coloso","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0140","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/hmg\/7.5.783","article-title":"Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture","volume":"7","author":"Cooper","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0145","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J Proteome Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0150","article-title":"Heat-shock protein 70 modulates toxic extracellular {alpha}-synuclein oligomers and rescues trans-synaptic toxicity","author":"Danzer","year":"2010","journal-title":"Faseb J"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2990.2003.00487.x","article-title":"Neurotrophins and neurodegeneration","volume":"29","author":"Dawbarn","year":"2003","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0160","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0304-4165(65)90430-7","article-title":"Degradation of cystaldimine, the product of oxidative deamination of cystamine","volume":"100","author":"Demarco","year":"1965","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0170","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.freeradbiomed.2007.12.015","article-title":"Cystamine restores GSTA3 levels in Vanin-1 null mice","volume":"44","author":"Di Leandro","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymthe.2004.09.007","article-title":"Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease","volume":"11","author":"Dong","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0180","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mds.20756","article-title":"CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease","volume":"21","author":"Dubinsky","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.disamonth.2007.02.004","article-title":"Autonomic dysfunction in Parkinson's disease","volume":"53","author":"Dubow","year":"2007","journal-title":"Dis Mon"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0149-7634(05)80185-X","article-title":"A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy","volume":"16","author":"Emerich","year":"1992","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0195","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/mds.10486","article-title":"Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease","volume":"18","author":"Fitzmaurice","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0200","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1471-4159.2004.02726.x","article-title":"Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation","volume":"91","author":"Fox","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.tpj.6500360","article-title":"Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease","volume":"6","author":"Fumagalli","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0210","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0963-6897(95)02030-6","article-title":"Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration","volume":"5","author":"Galpern","year":"1996","journal-title":"Cell Transplant"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0215","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pnpbp.2009.11.005","article-title":"Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor","volume":"34","author":"Gibrat","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0220","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bbrc.2004.12.066","article-title":"Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells","volume":"327","author":"Gorman","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0225","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/bj20021234","article-title":"Transglutaminases: nature's biological glues","volume":"368","author":"Griffin","year":"2002","journal-title":"Biochem J"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0230","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jns.2009.08.021","article-title":"Brainstem pathology and non-motor symptoms in PD","volume":"289","author":"Grinberg","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2009.05118.x","article-title":"The progression of pathology in Parkinson's disease","volume":"1184","author":"Halliday","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0240","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jmv.1890060210","article-title":"Inhibition of influenza A virus replication by rifampicin and selenocystamine","volume":"6","author":"Hamzehei","year":"1980","journal-title":"J Med Virol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0245","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.mcna.2008.09.002","article-title":"Movement disorders","volume":"93","author":"Harris","year":"2009","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0250","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/bbrc.1999.0337","article-title":"Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract","volume":"256","author":"Hazeki","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0255","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ncpneuro0924","article-title":"Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis","volume":"4","author":"Henchcliffe","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0260","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2003.tb07478.x","article-title":"The role of glial reaction and inflammation in Parkinson's disease","volume":"991","author":"Hirsch","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0265","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson's disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0270","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington's disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0275","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejphar.2008.06.078","article-title":"Beneficial effects of treatment with cystamine on brain in NZB\/WF1 mice","volume":"591","author":"Hsu","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0280","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1152\/physrev.1992.72.1.101","article-title":"Physiological actions of taurine","volume":"72","author":"Huxtable","year":"1992","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0285","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1073\/pnas.88.5.1913","article-title":"Glutathione deficiency leads to mitochondrial damage in brain","volume":"88","author":"Jain","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0290","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.bcp.2004.12.011","article-title":"Mechanism for the inhibition of transglutaminase 2 by cystamine","volume":"69","author":"Jeitner","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0295","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1073\/pnas.0438021100","article-title":"Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies","volume":"100","author":"Junn","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0300","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0305","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1212\/01.WNL.0000138500.73671.DC","article-title":"Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies","volume":"63","author":"Kaufmann","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0310","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1046\/j.0953-816x.2001.01534.x","article-title":"Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease","volume":"13","author":"Kirik","year":"2001","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0315","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/WCO.0b013e3280adc943","article-title":"Therapeutic approaches to inflammation in neurodegenerative disease","volume":"20","author":"Klegeris","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0320","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00415-007-0611-y","article-title":"Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study","volume":"254","author":"Klepac","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0325","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1517\/14656566.5.11.2255","article-title":"Pharmacological treatment of nephropathic cystinosis with cysteamine","volume":"5","author":"Kleta","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0330","doi-asserted-by":"crossref","first-page":"25497","DOI":"10.1074\/jbc.M400255200","article-title":"Hsp70 reduces alpha-synuclein aggregation and toxicity","volume":"279","author":"Klucken","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0335","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1006\/mcne.2000.0914","article-title":"Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2","volume":"16","author":"Knott","year":"2000","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0340","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/09553007014551521","article-title":"Further studies on protection of DNA against ionizing radiation","volume":"18","author":"Kollmann","year":"1970","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0345","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1006\/phrs.2002.0986","article-title":"Inhibitory effect of apoptosis in human astrocytes CCF-STTG1 cells by lemon oil","volume":"45","author":"Koo","year":"2002","journal-title":"Pharmacol Res"},{"issue":"Suppl 3","key":"10.1016\/j.pnpbp.2010.11.023_bb0350","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1002\/ana.10485","article-title":"In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease","volume":"53","author":"Kordower","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0355","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0360","first-page":"60","article-title":"Clinical aspects of bowel symptoms in Parkinson's disease","volume":"117","author":"Krogh","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0365","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O","article-title":"Huntington aggregates may not predict neuronal death in Huntington's disease","volume":"46","author":"Kuemmerle","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0370","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.2220","article-title":"Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future","volume":"16","author":"Lang","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0375","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jnutbio.2003.10.005","article-title":"Regulation of cysteine dioxygenase and gamma-glutamylcysteine synthetase is associated with hepatic cysteine level","volume":"15","author":"Lee","year":"2004","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0380","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1046\/j.1471-4159.1999.02018.x","article-title":"Tissue transglutaminase is increased in Huntington's disease brain","volume":"73","author":"Lesort","year":"1999","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0385","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1074\/jbc.M205812200","article-title":"Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders","volume":"278","author":"Lesort","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0390","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1523\/JNEUROSCI.15-12-07810.1995","article-title":"Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease","volume":"15","author":"Levivier","year":"1995","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0395","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jnnp.2003.033530","article-title":"Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach","volume":"76","author":"Lewis","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0400","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/3033","article-title":"DRPLA aggregation and transglutaminase, revisited","volume":"20","author":"Lorand","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0405","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00240602","article-title":"Transglutaminases","volume":"58","author":"Lorand","year":"1984","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0410","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.phrs.2008.09.006","article-title":"alpha-Synuclein: a therapeutic target for Parkinson's disease?","volume":"58","author":"Maguire-Zeiss","year":"2008","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0415","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00023210-200317100-00004","article-title":"Neuroprotective strategies in Parkinson's disease: an update on progress","volume":"17","author":"Mandel","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0420","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.cdd.4401093","article-title":"Tissue transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease","volume":"9","author":"Mastroberardino","year":"2002","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0425","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0430","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.21751","article-title":"Glial reactions in Parkinson's disease","volume":"23","author":"McGeer","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0435","first-page":"83","article-title":"Inflammation in Parkinson's disease","volume":"86","author":"McGeer","year":"2001","journal-title":"Adv Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0440","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cne.10295","article-title":"Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6\/2 transgenic mice","volume":"449","author":"Meade","year":"2002","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0445","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1074\/jbc.M806269200","article-title":"Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease","volume":"284","author":"Mitra","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0450","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1523\/JNEUROSCI.22-21-09267.2002","article-title":"Purification of polyglutamine aggregates and identification of elongation factor-1alpha and heat shock protein 84 as aggregate-interacting proteins","volume":"22","author":"Mitsui","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0455","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","article-title":"Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients","volume":"165","author":"Mogi","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0460","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrn1587","article-title":"Modulation of neurodegeneration by molecular chaperones","volume":"6","author":"Muchowski","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0465","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1254\/jjp.28.259","article-title":"A modulating role of taurine on release of acetylcholine and norepinephrine from neuronal tissues","volume":"28","author":"Muramatsu","year":"1978","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0470","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0301-0082(00)00014-9","article-title":"Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease","volume":"63","author":"Murer","year":"2001","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0475","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2307\/3579612","article-title":"Effect of polyamine-induced compaction and aggregation of DNA on the formation of radiation-induced strand breaks: quantitative models for cellular radiation damage","volume":"148","author":"Newton","year":"1997","journal-title":"Radiat Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0480","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0485","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1749-6632.2009.04943.x","article-title":"Biomarkers in Huntington's and Parkinson's Disease","volume":"1180","author":"O'Keeffe","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0490","doi-asserted-by":"crossref","first-page":"pe16","DOI":"10.1126\/sageke.2002.41.pe16","article-title":"Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease","volume":"2002","author":"Ogawa","year":"2002","journal-title":"Sci Aging Knowl Environ"},{"issue":"Suppl 2","key":"10.1016\/j.pnpbp.2010.11.023_bb0495","first-page":"S101","article-title":"Why have we failed to achieve neuroprotection in Parkinson's disease?","volume":"64","author":"Olanow","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0500","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00726-010-0500-z","article-title":"Transglutaminase 2: a multi-functional protein in multiple subcellular compartments","volume":"39","author":"Park","year":"2010","journal-title":"Amino Acids"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0505","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-1-4757-0402-0_18","article-title":"The role of taurine in nervous tissue: its effects on ionic fluxes","volume":"139","author":"Pasantes-Morales","year":"1981","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0510","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","article-title":"Microglial activation correlates with severity in Huntington disease: a clinical and PET study","volume":"66","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0515","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/BF01291884","article-title":"Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease","volume":"104","author":"Pearce","year":"1997","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0520","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1083\/jcb.143.6.1457","article-title":"Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation","volume":"143","author":"Perez","year":"1998","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0525","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0304-3940(86)90320-4","article-title":"Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients","volume":"67","author":"Perry","year":"1986","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0530","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1139\/y92-004","article-title":"Cysteamine in combination with N-acetylcysteine prevents acetaminophen-induced hepatotoxicity","volume":"70","author":"Peterson","year":"1992","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0535","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1471-4159.2008.05665.x","article-title":"Cystamine prevents haloperidol-induced decrease of BDNF\/TrkB signaling in mouse frontal cortex","volume":"107","author":"Pillai","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0540","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1016\/j.jchromb.2009.05.041","article-title":"Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism","volume":"877","author":"Pinto","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0545","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03255.x","article-title":"Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease","volume":"94","author":"Pinto","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0550","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0304-4165(92)90124-D","article-title":"Enzymatic synthesis of S-aminoethyl-L-cysteine from pantetheine","volume":"1116","author":"Pitari","year":"1992","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 17","key":"10.1016\/j.pnpbp.2010.11.023_bb0555","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1002\/mds.21681","article-title":"Dysautonomia and cognitive dysfunction in Parkinson's disease","volume":"22","author":"Poewe","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0560","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.expneurol.2004.11.030","article-title":"Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons","volume":"192","author":"Porritt","year":"2005","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0565","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(76)92842-7","article-title":"Cysteamine, methionine, and penicillamine in the treatment of paracetamol poisoning","volume":"2","author":"Prescott","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0570","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1471-4159.1994.62010376.x","article-title":"Oxidative stress induces apoptosis in embryonic cortical neurons","volume":"62","author":"Ratan","year":"1994","journal-title":"J Neurochem"},{"issue":"Suppl 4","key":"10.1016\/j.pnpbp.2010.11.023_bb0575","first-page":"IV\/8","article-title":"Is there neuroprotection in Parkinson syndrome?","volume":"247","author":"Riederer","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0580","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2009.01.038","article-title":"A Nurr1\/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death","volume":"137","author":"Saijo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0585","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/phrs.2002.0955","article-title":"Modulation of inflammatory paw oedema by cysteamine in the rat","volume":"45","author":"Salam","year":"2002","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0590","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","article-title":"Early and progressive accumulation of reactive microglia in the Huntington disease brain","volume":"60","author":"Sapp","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0595","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(00)81782-1","article-title":"Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions","volume":"95","author":"Saudou","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0600","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1212\/WNL.58.suppl_1.S9","article-title":"Neuroprotection and dopamine agonists","volume":"58","author":"Schapira","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0605","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0278-5846(96)00103-0","article-title":"Reduced intravenous glutathione in the treatment of early Parkinson's disease","volume":"20","author":"Sechi","year":"1996","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0610","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cne.903420302","article-title":"Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs","volume":"342","author":"Seroogy","year":"1994","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0615","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/1357-2725(95)00038-Q","article-title":"The uptake and metabolism of cystamine and taurine by isolated perfused rat and rabbit lungs","volume":"27","author":"Sharma","year":"1995","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0620","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.pnpbp.2008.06.003","article-title":"Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice","volume":"32","author":"Shieh","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0625","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1083\/jcb.200508072","article-title":"Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity","volume":"171","author":"Shin","year":"2005","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0630","doi-asserted-by":"crossref","first-page":"23727","DOI":"10.1074\/jbc.M503326200","article-title":"The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways","volume":"280","author":"Shin","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0635","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1212\/WNL.36.8.1099","article-title":"Huntington's disease: effect of cysteamine, a somatostatin-depleting agent","volume":"36","author":"Shults","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0640","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410360305","article-title":"Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia","volume":"36","author":"Sian","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0645","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/exnr.1999.7170","article-title":"Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease","volume":"159","author":"Singhrao","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0650","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2307\/3576807","article-title":"Equilibrium dialysis studies of the binding of radioprotector compounds to DNA","volume":"107","author":"Smoluk","year":"1986","journal-title":"Radiat Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0655","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0304-3940(92)90355-B","article-title":"Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease","volume":"142","author":"Sofic","year":"1992","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0660","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbadis.2007.12.006","article-title":"Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease","volume":"1782","author":"Stack","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0665","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0670","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2307\/3571989","article-title":"The radioprotection of Saccharomyces cerevisiae by cystamine as measured by different criteria of cell damage","volume":"28","author":"Stuart","year":"1966","journal-title":"Radiat Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0675","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12640-009-9053-x","article-title":"Mutant alpha-synuclein overexpression mediates early proinflammatory activity","volume":"16","author":"Su","year":"2009","journal-title":"Neurotox Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0680","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.neurobiolaging.2007.04.006","article-title":"Synuclein activates microglia in a model of Parkinson's disease","volume":"29","author":"Su","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0685","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/187152809789352249","article-title":"Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models","volume":"8","author":"Sugama","year":"2009","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0690","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainres.2010.03.079","article-title":"Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice","volume":"1335","author":"Sun","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0695","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainresbull.2006.10.029","article-title":"Imaging microglial activation in Huntington's disease","volume":"72","author":"Tai","year":"2007","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0700","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/hmg\/ddg074","article-title":"Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein","volume":"12","author":"Taylor","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0705","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.0953-816X.2004.03139.x","article-title":"Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice","volume":"19","author":"Thiruchelvam","year":"2004","journal-title":"Eur J Neurosci"},{"issue":"Suppl","key":"10.1016\/j.pnpbp.2010.11.023_bb0710","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.parkreldis.2007.06.007","article-title":"The premotor phase of Parkinson's disease","volume":"13","author":"Tolosa","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0715","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1089\/aid.2009.0091","article-title":"Sulfur metabolism in AIDS: cystamine as an anti-HIV agent","volume":"25","author":"Toohey","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0720","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.neurobiolaging.2005.04.004","article-title":"Neuroprotective effects of cystamine in aged parkinsonian mice","volume":"27","author":"Tremblay","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0725","doi-asserted-by":"crossref","first-page":"1281S","DOI":"10.1093\/jn\/126.suppl_4.1281S","article-title":"Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status\u2013a possible element of the extracellular antioxidant defense system","volume":"126","author":"Ueland","year":"1996","journal-title":"J Nutr"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0730","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","article-title":"Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease","volume":"95","author":"Van Raamsdonk","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0735","first-page":"51","article-title":"Interaction of sulfur-containing radioprotectors with DNA: a spectrophotometric study","volume":"12","author":"Vasilescu","year":"1980","journal-title":"Physiol Chem Phys"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0740","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1471-4159.2007.04494.x","article-title":"Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro","volume":"102","author":"Volpicelli","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0745","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.biopsych.2005.08.025","article-title":"Regional- and age-dependent reduction in trkB receptor expression in the hippocampus is associated with altered spine morphologies","volume":"59","author":"von Bohlen und Halbach","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0750","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2004.12.011","article-title":"Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6\/2 mouse model of Huntington's disease","volume":"231","author":"Wang","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0755","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bjp.0707167","article-title":"Inflammation as a causative factor in the aetiology of Parkinson's disease","volume":"150","author":"Whitton","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2004.12.055","article-title":"The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model","volume":"1038","author":"Yasuhara","year":"2005","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0765","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease","volume":"19","author":"Zhang","year":"2005","journal-title":"Faseb J"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0770","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2307\/3577140","article-title":"Radioprotection of DNA by thiols: relationship between the net charge on a thiol and its ability to protect DNA","volume":"114","author":"Zheng","year":"1988","journal-title":"Radiat Res"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0775","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","article-title":"Role of brain-derived neurotrophic factor in Huntington's disease","volume":"81","author":"Zuccato","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0780","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1750-3639.2007.00111.x","article-title":"Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease","volume":"18","author":"Zuccato","year":"2008","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pnpbp.2010.11.023_bb0785","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.cdd.4402261","article-title":"Mutant huntingtin can paradoxically protect neurons from death","volume":"15","author":"Zuchner","year":"2008","journal-title":"Cell Death Differ"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610004501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610004501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T13:35:40Z","timestamp":1711978540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584610004501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":158,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0278584610004501"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2010.11.023","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}